Strides Pharma Science reported a strong set of financial results for the third quarter, delivering sharp growth in profitability and steady improvement in operating performance on a year-on-year basis.
The pharmaceutical company posted a net profit of ₹202 crore in Q3, marking a significant jump from ₹88 crore in the corresponding quarter last year. The sharp rise in profit was supported by better operating leverage and improved efficiency across key business segments.
Revenue for the quarter came in at ₹1,194.6 crore, reflecting a growth of 3.6% compared to ₹1,153.6 crore reported in the same period last year. While topline growth remained moderate, consistent demand across regulated markets and portfolio optimisation helped maintain revenue stability.
Earnings before interest, tax, depreciation and amortisation (EBITDA) rose 12.2% year-on-year to ₹235.8 crore, up from ₹210.2 crore in Q3 of the previous financial year. EBITDA margin expanded to 19.7% during the quarter, compared with 18.2% a year earlier.
